Latest Conference Coverage


Q&A: Genetic Ancestry and Alzheimer Disease Risk

Q&A: Genetic Ancestry and Alzheimer Disease Risk

August 6th 2020

Katrina Celis, MD, a postdoctoral fellow at the University of Miami Miller School of Medicine, discussed how ancestral genetics can play a key role in Alzheimer disease risk.


Sargramostim Shows Safety and Promise as Potential Alzheimer Treatment

Sargramostim Shows Safety and Promise as Potential Alzheimer Treatment

August 6th 2020

The investigators wrote that the Alzheimer’s Association “Part the Cloud” funded 24-week treatment trial is now warranted after sargramostim showed a safe and tolerable profile.


Dementia-Related Psychosis Places Heavy Burden on Patients and Caretakers

Dementia-Related Psychosis Places Heavy Burden on Patients and Caretakers

August 5th 2020

Data from 2 posters presented at AAIC 2020 suggest that there is an unmet need for safe and effective treatments for patients who experience dementia-related psychosis.


Raymond S. Turner, MD, PhD: Safety Results for Nilotinib in Alzheimer

Raymond S. Turner, MD, PhD: Safety Results for Nilotinib in Alzheimer

August 5th 2020

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.


12 Modifiable Risk Factors to Reduce Dementia Risk

12 Modifiable Risk Factors to Reduce Dementia Risk

August 3rd 2020

Excessive alcohol intake, head injury, and air pollution are among the newest dementia risk factors added to the Lancet Commission report.


Nilotinib Safety Profile Sets Agent Up For Phase 3 Study

Nilotinib Safety Profile Sets Agent Up For Phase 3 Study

August 1st 2020

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.


Katrina Celis, MD: Ancestral Genetics and the Impact on Alzheimer Disease Risk

Katrina Celis, MD: Ancestral Genetics and the Impact on Alzheimer Disease Risk

August 1st 2020

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed her study presented at AAIC 2020 that examined Alzheimer risk associated with APOE ε4 in different genetic populations.


Hypertension, Diabetes, High BMI All Early Life Risk Factors for Dementia

Hypertension, Diabetes, High BMI All Early Life Risk Factors for Dementia

July 30th 2020

Multiple studies presented at AAIC 2020 highlight and confirm previous hypotheses of the role that early life cardiovascular risk factors play for individuals who develop late life dementia.


VU319 Shows Safe Profile and Potential as M1 Allosteric Modulator for MCI

VU319 Shows Safe Profile and Potential as M1 Allosteric Modulator for MCI

July 30th 2020

The data suggests that a planned multiple ascending dose study and a phase 2a proof-of-concept study in patients with mild cognitive impairment could be on the way.


Nilotinib Has Safe and Tolerable Profile in Alzheimer Disease

Nilotinib Has Safe and Tolerable Profile in Alzheimer Disease

July 29th 2020

Results presented virtually at AAIC 2020 support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.


Candesartan Shows Signs of Neuroprotection in Older Adults With MCI and Hypertension

Candesartan Shows Signs of Neuroprotection in Older Adults With MCI and Hypertension

July 29th 2020

Compared to treatment with lisinopril, those treated with the angiotensin receptor blocker candesartan showed improvements on the Trial Making Test part A and B and Hopkins Verbal Learning Test-Revised delayed recall.


Pimavanserin Reduces Dementia-Related Psychosis Symptoms

Pimavanserin Reduces Dementia-Related Psychosis Symptoms

July 29th 2020

Additional data presented at AAIC 2020 shows the clinical benefit pimavanserin has on dementia-related psychosis while the agent awaits a PDUFA date of April 3, 2021.


P-Tau217 May Detect Alzheimer Disease, Brain Amyloidosis, Tauopathy

P-Tau217 May Detect Alzheimer Disease, Brain Amyloidosis, Tauopathy

July 28th 2020

The performance of p-tau217 was similar to significantly more costly methods, such as PET imaging and measuring cerebrospinal fluid biomarkers.


Influenza, Pneumonia Vaccination May Reduce Alzheimer Disease Risk

Influenza, Pneumonia Vaccination May Reduce Alzheimer Disease Risk

July 27th 2020

A trio of studies presented at AAIC 2020 suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.


Matthew Robbins, MD: Headaches Associated With COVID-19

Matthew Robbins, MD: Headaches Associated With COVID-19

July 21st 2020

The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.


Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination Treatment

Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination Treatment

July 15th 2020

The internal medicine resident physician at Montefiore Health System provided an overview of the study he and colleagues conducted on patients using onabotulinumtoxinA and CGRP agents in tandem.


Kathleen Digre, MD, on Eye Pain and Photophobia in Migraine

Kathleen Digre, MD, on Eye Pain and Photophobia in Migraine

July 14th 2020

Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic.


Roger Cady, MD: Rapid Effect of Eptinezumab on Migraine

Roger Cady, MD: Rapid Effect of Eptinezumab on Migraine

July 14th 2020

The head of Neurology Medical at Lundbeck Seattle Biopharmaceuticals offers perspective on the findings and what impact eptinezumab may have on migraine care.


Total Migraine Pain Burden Reduced With Galcanezumab in Post-Hoc Analysis

Total Migraine Pain Burden Reduced With Galcanezumab in Post-Hoc Analysis

July 13th 2020

Treatment with galcanezumab (Emgality; Eli Lilly) was associated with improvements in total pain burden for patients with both chronic and episodic migraine compared to placebo groups.


Matthew Robbins, MD: Residency During COVID-19

Matthew Robbins, MD: Residency During COVID-19

July 9th 2020

The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.


Chia-Chun Chiang, MD: Collecting Real-World Data Following FDA Approvals

Chia-Chun Chiang, MD: Collecting Real-World Data Following FDA Approvals

July 7th 2020

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.


Long-Term Safety Study Confirms Efficacy of ADAM Zolmitriptan in Acute Migraine

Long-Term Safety Study Confirms Efficacy of ADAM Zolmitriptan in Acute Migraine

July 7th 2020

The FDA accepted an NDA for Zosano’s ADAM zolmitriptan (Qytripta) in the acute treatment of migraine in early March, with a PDUFA date set for mid-October 2020.


Chia-Chun Chiang, MD: Variations in FDA Approved Migraine Medications

Chia-Chun Chiang, MD: Variations in FDA Approved Migraine Medications

June 27th 2020

The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.


Migraine Care During a Pandemic: Takeaways for the Future

Migraine Care During a Pandemic: Takeaways for the Future

June 24th 2020

In part 2 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, describes the lessons he and his residents have learned during the COVID-19 pandemic and how they'll impact the future of care.


Chia-Chun Chiang, MD: Comparing Ubrogepant Study Results

Chia-Chun Chiang, MD: Comparing Ubrogepant Study Results

June 23rd 2020

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed whether her and colleagues recent study results on ubrogepant aligned with previous study findings.


Fred Cohen, MD: Combining CGRPs and OnabotulinumtoxinA for Migraine Prevention

Fred Cohen, MD: Combining CGRPs and OnabotulinumtoxinA for Migraine Prevention

June 22nd 2020

The internal medicine resident physician at Montefiore Health System offers insight into the combined use of CGRP medications and Botox to optimize migraine prevention in patients who have inadequate response with Botox alone.


Neurology and COVID-19: Adapting Specialty Care During the Pandemic

Neurology and COVID-19: Adapting Specialty Care During the Pandemic

June 20th 2020

In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.


Gilbert L'Italien, PhD: The Economic Impact of MIDAS Disability Grades in Migraine

Gilbert L'Italien, PhD: The Economic Impact of MIDAS Disability Grades in Migraine

June 20th 2020

The senior VP of Global Health Economics and Outcomes Research and Epidemiology at Biohaven Pharmaceuticals discussed the findings from a poster presentation on the economic impact of migraine disability at AHS 2020.


High Frequency Episodic Migraine Has Similar Burden to Low Frequency Chronic Migraine

High Frequency Episodic Migraine Has Similar Burden to Low Frequency Chronic Migraine

June 19th 2020

Treatment needs of those with high frequency episodic migraine may be similar to those with low frequency chronic migraine.


Ubrogepant Effective for Migraine Patients With Insufficient Triptan Response

Ubrogepant Effective for Migraine Patients With Insufficient Triptan Response

June 19th 2020

The recently approved Allergan agent reported lower rates of functional disability and better overall satisfaction with treatment, as well as similar success for those who did not experience efficacy with triptans.

© 2024 MJH Life Sciences

All rights reserved.